Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Navitoclax. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2L1 known ✓ | Q07817 | 19/20 | 1.00 |
| ▸ | BCL2 known ✓ | P10415 | 16/20 | 1.00 |
| ▸ | BCL2L2 known ✓ | Q92843 | 2/20 | 1.00 |
| ▸ | BAD | Q92934 | 3/20 | 1.00 |
| ▸ | BCL2L11 | O43521 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | MCL1 | Q07820 | 1/20 | 1.00 |
| ▸ | ASPH | Q12797 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Navitoclax SCHEMBL10316178 | 1.00 | BCL2L1 (1.00) | BCL2L1BCL2BADBCL2L2BCL2L11 | |
| Navitoclax SCHEMBL30255921 | 1.00 | BCL2L1 (1.00) | BCL2L1BCL2BADBCL2L2BCL2L11 | |
| Navitoclax SCHEMBL15005512 | 1.00 | BCL2L1 (1.00) | BCL2L1BCL2BADBCL2L2BCL2L11 | |
| Navitoclax SCHEMBL29363785 | 1.00 | BCL2L1 (1.00) | BCL2L1BCL2BADBCL2L2BCL2L11 | |
| SCHEMBL2022422 | 0.98 | BCL2L1 (0.96) | BCL2L1BCL2BADBCL2L2BCL2L11 | |
| SCHEMBL2022805 | 0.97 | BCL2L1 (0.94) | BCL2L1BCL2BADBCL2L2BCL2L11 | |
| SCHEMBL19911641 | 0.97 | BCL2L1 (0.94) | BCL2L1BCL2BADBCL2L2BCL2L11 | |
| SCHEMBL23258372 | 0.96 | BCL2L1 (0.93) | BCL2L1BCL2BADBCL2L2BCL2L11 | |
| SCHEMBL1955579 | 0.96 | BCL2L1 (0.93) | BCL2L1BCL2BADBCL2L2BCL2L11 | |
| SCHEMBL1628079 | 0.96 | BCL2L1 (0.93) | BCL2L1BCL2BADBCL2L2BCL2L11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 5257 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260146233-A1 | HIF-1a STABILIZATION FOR TISSUE REGENERATION | THE UNIVERSITY OF HONG KONG (CN) | 2026-05-28 | — | — | US | claimed |
| CN-117820191-B | Diphenylamine compound and preparation method, application and pharmaceutical composition thereof | FUDAN UNIVERSITY (CN) | 2026-05-26 | — | — | CN | claimed |
| US-20260124242-A1 | EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES FROM LIQUID TUMORS AND THERAPEUTIC USES THEREOF | IOVANCE BIOTHERAPEUTICS INC (US) | 2026-05-07 | — | — | US | claimed |
| US-20260124240-A1 | DRUG RESISTANT IMMUNE CELLS | UNIV CALIFORNIA (US) | 2026-05-07 | — | — | US | claimed |
| US-20260108534-A1 | LIPOSOMAL FORMULATIONS OF BCL INHIBITORS | JAZZ PHARMACEUTICALS THERAPEUTICS INC (US) | 2026-04-23 | — | — | US | claimed |
| EP-4727563-A1 | AGENTS FOR USE IN A METHOD OF TREATING AN ACUTE LIVER DISEASE SUBJECT | Beatson Institute for Cancer Research (GB) | 2026-04-22 | — | — | EP | claimed |
| US-12599615-B2 | Use of carotenoids in the treatment of senescence-related diseases | GAT THERAPEUTICS, S.L. (ES) | 2026-04-14 | — | — | US | claimed |
| EP-4719403-A1 | METHODS OF TREATING CANCER IN BCL2 INHIBITOR NAIVE SUBJECTS | Curis, Inc. (US) | 2026-04-08 | — | — | EP | claimed |
| US-12595517-B2 | Method to treat and stratify a patient suffering from a cancer | INSERM (INSTITUTE NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2026-04-07 | — | — | US | claimed |
| US-20260083752-A1 | PHARMACEUTICAL METHODS, COMPOSITIONS AND COMBINATIONS | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2026-03-26 | — | — | US | claimed |
| WO-2009064938-A1 | METHOD OF TREATING ARTHRITIS | ABBOTT LABORATORIES (US) | 2009-05-22 | — | — | WO | claimed |
| US-20080269067-A1 | Companion diagnostic assays for cancer therapy | ABBOTT LABORATORIES (US) | 2008-10-30 | — | — | US | claimed |
| US-20080233567-A1 | Companion diagnostic assays for cancer therapy | ABBOTT LABORATORIES | 2008-09-25 | — | — | US | claimed |
| US-20080199873-A1 | Companion diagnostic assays for cancer therapy | ABBOTT LABORATORIES | 2008-08-21 | — | — | US | claimed |
| US-20080193943-A1 | Companion diagnostic assays for cancer therapy | ABBOTT LABORATORIES | 2008-08-14 | — | — | US | claimed |
| US-20080182845-A1 | METHOD OF PREVENTING OR TREATING ORGAN, HEMATOPOIETIC STEM CELL OR BONE MARROW TRANSPLANT REJECTION | ABBOTT LABORATORIES (US) | 2008-07-31 | — | — | US | claimed |
| US-20080160545-A1 | Pro-GRP as a surrogate marker to predict and monitor response to Bcl-2 inhibitor therapy | ABBOTT LABORATORIES (US) | 2008-07-03 | — | — | US | claimed |
| US-7390799-B2 | Apoptosis promoters | ABBOTT LABORATORIES (US) | 2008-06-24 | — | — | US | claimed |
| WO-2008070663-A2 | COMPANION DIAGNOSTIC ASSAYS FOR CANCER THERAPY | ABBOTT LABORATORIES (US) | 2008-06-12 | — | — | WO | claimed |
| WO-2008064116-A2 | METHOD OF PREVENTING OR TREATING ORGAN, HEMATOPOIETIC STEM CELL OR BONE MARROW TRANSPLANT REJECTION | ABBOTT LABORATORIES (US) | 2008-05-29 | — | — | WO | claimed |